Next 10 |
NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the...
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple scl...
2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...
2024-05-14 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-12 07:04:52 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: The Week Ahead
2024-05-10 15:00:11 ET More on the markets SPY: Growing Signs The Market Is Overbought SPY: The Shrinking Market For U.S. Companies SPY: Stronger Than Ever For the second consecutive week, investors purchase ETFs and conventional funds Earnings estima...
2024-05-03 09:53:55 ET Summary TG Therapeutics beat first quarter revenue expectations and raised the full-year revenue guidance by $40 million at the mid-point. Work on the subcutaneous version of Briumvi continues and could represent the next step for increased long-term growth ...
2024-05-02 22:21:08 ET TG Therapeutics, Inc. (TGTX) Q1 2024 Earnings Conference Call May 01, 2024 08:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - President and Chief Executive Officer Adam Waldman -...
2024-05-01 09:24:55 ET More on TG Therapeutics TG Therapeutics: The Cloud Over Briumvi TG Therapeutics: BRIUMVI Development Could Lead To Great Results TG Therapeutics: Briumvi Growth Story Appears Intact TG Therapeutics wins VA contract for Briumvi T...
2024-05-01 07:25:14 ET More on TG Therapeutics TG Therapeutics: The Cloud Over Briumvi TG Therapeutics: BRIUMVI Development Could Lead To Great Results TG Therapeutics: Briumvi Growth Story Appears Intact TG Therapeutics wins VA contract for Briumvi T...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the...
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple scl...
2024-05-14 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...